Literature DB >> 9462636

Lack of C/EBP alpha gene expression results in increased DNA synthesis and an increased frequency of immortalization of freshly isolated mice [correction of rat] hepatocytes.

H E Soriano1, D C Kang, M J Finegold, M J Hicks, N D Wang, W Harrison, G J Darlington.   

Abstract

The CCAAT/enhancer binding protein alpha (C/EBP alpha) binds to specific promoter sequences and directs transcription of many genes expressed in the liver. Overexpression of C/EBP alpha in established cell lines inhibits cell proliferation. Primary hepatocytes from newborn C/EBP alpha(-/-) mice and normal littermates were used to determine whether the absence of C/EBP alpha increased proliferation and/or transformation of these cells in vitro. DNA synthesis, as measured by bromodeoxyuridine (BrdU) incorporation 24 hours postharvest, was fourfold higher in cells from C/EBP alpha(-/-) pups. Established cell lines were derived from 7 of 8 hepatocyte cultures initiated from null mutants, 4 of 23 cultures from heterozygotes, and 0 of 12 cultures from wild-type animals. C/EBP alpha(-/-) cultures had epithelial morphology, showed bile canaliculi, and expressed albumin messenger RNA (mRNA). When cultured on Matrigel, which promotes differentiation, cell lines derived from C/EBP alpha(-/-) mice formed cords and increased albumin mRNA expression by 1.7- to 3.8-fold. C/EBP alpha(-/-) cell lines exhibited rapid growth and rapid accumulation of chromosomal abnormalities, and were capable of forming nodules when inoculated into the abdominal subcutaneous tissue of nude mice. Our data show that C/EBP alpha is an important regulator of hepatocyte proliferation and participates in the maintenance of the nontransformed hepatic phenotype in vitro.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9462636     DOI: 10.1002/hep.510270212

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

Review 1.  A tumor suppressor role for C/EBPα in solid tumors: more than fat and blood.

Authors:  A R Lourenço; P J Coffer
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

2.  Dephosphorylated C/EBPalpha accelerates cell proliferation through sequestering retinoblastoma protein.

Authors:  Guo-Li Wang; Nikolai A Timchenko
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

3.  C/EBPalpha triggers proteasome-dependent degradation of cdk4 during growth arrest.

Authors:  Hongmei Wang; Triona Goode; Polina Iakova; Jeffrey H Albrecht; Nikolai A Timchenko
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

4.  Restoration of C/EBPα in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis.

Authors:  Yuhsin V Wu; Tomoyo Okada; Penelope DeCarolis; Nicholas Socci; Rachael O'Connor; Rula C Geha; C Joy Somberg; Cristina Antonescu; Samuel Singer
Journal:  Genes Chromosomes Cancer       Date:  2011-12-14       Impact factor: 5.006

5.  Increased expression of enzymes of triglyceride synthesis is essential for the development of hepatic steatosis.

Authors:  Jingling Jin; Polina Iakova; Meghan Breaux; Emily Sullivan; Nicole Jawanmardi; Dahu Chen; Yanjun Jiang; Estela M Medrano; Nikolai A Timchenko
Journal:  Cell Rep       Date:  2013-03-14       Impact factor: 9.423

6.  Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity.

Authors:  Guo-Li Wang; Polina Iakova; Margie Wilde; Samir Awad; Nikolai A Timchenko
Journal:  Genes Dev       Date:  2004-04-15       Impact factor: 11.361

7.  CCAAT/enhancer binding protein alpha uses distinct domains to prolong pituitary cells in the growth 1 and DNA synthesis phases of the cell cycle.

Authors:  Weiqun Liu; John F Enwright; William Hyun; Richard N Day; Fred Schaufele
Journal:  BMC Cell Biol       Date:  2002-03-21       Impact factor: 4.241

Review 8.  Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.

Authors:  Ryan L Setten; Helen L Lightfoot; Nagy A Habib; John J Rossi
Journal:  Curr Pharm Biotechnol       Date:  2018       Impact factor: 2.837

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.